Summary of prospective trial results of the pediatric regimen in adolescent and adult ALL
| Trial . | Description . | No. evaluable . | Participant age, y . | EFS, % (95% CI) . | OS, % (95% CI) . |
|---|---|---|---|---|---|
| CALGB 104036 | Phase 2 single-arm multicenter trial conducted by the US adult cooperative groups using a pediatric regimen based on COG AALL0232 | 295 | 17-39 | 3 y, 59 (54%-65%) | 3 y, 73 (68%-78%) |
| DFCI 01-17520 | Multicenter trial conducted in the United States and Canada utilizing a pediatric-inspired regimen | 92 | 18-50 | 4 y, 58 (47%-68%) | 4 y, 67 (56%-76%) |
| GRAALL-200319 | Phase 2 multicenter trial conducted by the GRAALL adult cooperative group across France, Belgium, Switzerland evaluating a pediatric-inspired regimen | 225 | 15-60 | 3.5 y, 55 (48%-62%) | 3.5 y, 60 (53%-66%) |
| GRAALL-200518 | Multicenter successor trial of GRAALL-2003; included a randomization to standard or hyperfractionated cyclophosphamide | 787 | 18-59 | 5 y, 52.2 (48.5%-55.7%) | 5 y, 58.5 (54.8%-61.9%) |
| PETHEMA ALL-9655 | Multicenter trial conducted by the Spanish adult cooperative group utilizing a common pediatric regimen in adolescents and young adults with SR ALL | 81 | 15-30 | 6 y, 61 (51%-72%) | 6 y, 69 (59%-79%) |
| MDACC24 | Single-center trial conducted by MDACC evaluating an augmented BFM pediatric regimen | 106 | 13-39 | Not provided | 5 y, 60% |
| NOPHO ALL200821 | Multicenter protocol conducted by the Nordic cooperative group evaluating a common pediatric regimen across children, adolescents, and adults | 221* | 18-45 | 5 y, 74% ± 4%† | 5 y, 78% ± 3%† |
| Trial . | Description . | No. evaluable . | Participant age, y . | EFS, % (95% CI) . | OS, % (95% CI) . |
|---|---|---|---|---|---|
| CALGB 104036 | Phase 2 single-arm multicenter trial conducted by the US adult cooperative groups using a pediatric regimen based on COG AALL0232 | 295 | 17-39 | 3 y, 59 (54%-65%) | 3 y, 73 (68%-78%) |
| DFCI 01-17520 | Multicenter trial conducted in the United States and Canada utilizing a pediatric-inspired regimen | 92 | 18-50 | 4 y, 58 (47%-68%) | 4 y, 67 (56%-76%) |
| GRAALL-200319 | Phase 2 multicenter trial conducted by the GRAALL adult cooperative group across France, Belgium, Switzerland evaluating a pediatric-inspired regimen | 225 | 15-60 | 3.5 y, 55 (48%-62%) | 3.5 y, 60 (53%-66%) |
| GRAALL-200518 | Multicenter successor trial of GRAALL-2003; included a randomization to standard or hyperfractionated cyclophosphamide | 787 | 18-59 | 5 y, 52.2 (48.5%-55.7%) | 5 y, 58.5 (54.8%-61.9%) |
| PETHEMA ALL-9655 | Multicenter trial conducted by the Spanish adult cooperative group utilizing a common pediatric regimen in adolescents and young adults with SR ALL | 81 | 15-30 | 6 y, 61 (51%-72%) | 6 y, 69 (59%-79%) |
| MDACC24 | Single-center trial conducted by MDACC evaluating an augmented BFM pediatric regimen | 106 | 13-39 | Not provided | 5 y, 60% |
| NOPHO ALL200821 | Multicenter protocol conducted by the Nordic cooperative group evaluating a common pediatric regimen across children, adolescents, and adults | 221* | 18-45 | 5 y, 74% ± 4%† | 5 y, 78% ± 3%† |
GRALL, Group for Research on Adult Acute Lymphoblastic Leukemia; MDACC, MD Anderson Cancer Center; No., number; NOPHO, Nordic Society of Pediatric Hematology and Oncology; PETHEMA, Programa Español de Tratamiento en Hematología; SR, standard risk.
A total of 1509 participants were reported, including children and adolescents; the table describes results for the 221 young adults.
95% CI provided in a different format (as reported in the referenced article).